Clinical Trial Results:
Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral activity measured by functional MRI during processing of emotional stimuli in patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled study with an open extension period of 6 months with agomelatine (25 mg).Comparison to functional MRI profiles of healthy volunteers.
Summary
|
|
EudraCT number |
2007-005564-27 |
Trial protocol |
FR |
Global completion date |
19 Oct 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jul 2016
|
First version publication date |
31 Jul 2015
|
Other versions |
|
Summary report(s) |
Synopsis dated on 10-October-2012 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.